Skin carcinomas in organ-transplant recipients: from early oncogenic events to therapy

Author(s):
Graaf, Y.G.L. de
Published
2008
Publication type
Doctoral Thesis

Abstract

Skin carcinomas develop at a high rate in organ-transplant recipients who are kept on immune suppressive drugs to prevent graft rejection. The present study dealt with a broad range of aspects of this elevated carcinoma risk, starting from the earliest oncogenic events to the ultimate therapy. Advancements on any of these aspects may be of significant benefit to the patient and his/her physician in the management of multiple and progressive skin carcinomas. The studies presented in Chapter 2 - 4 focused on the early pathogenesis of skin cancer in organ-transplant recipients to gain a better understanding of the underlying mechanism(s) of the increased skin cancer risk in these patients. We specifically focused on the role of p53 and beta-PV in early skin carcinogenesis. The clinical studies in Chapter 5 - 7 investigated the management of skin cancer in organ-transplant recipients.

Skin cancerOrgan-transplant recipientsp53Beta-papillomarvirusPreventionTreatment
Defense date
2008-01-23
Language
English
Supervisor(s)
Willemze, R.
Advisor(s)
Bouwes Bavinck, J.N.; Gruijl, F.R. de
Qualification
Ph.D.
Degree granting institution
Leiden University Medical Center (LUMC), Leiden University, Leiden
Publisher
Department of Dermatology, Faculty of Medicine, Leiden University Medical Center (LUMC), Leiden University
hdl
1887/12579

Funding

Sponsorship
Astellas Pharma, Bauerfeind, Eucerin, Fagron BV, Galderma, GSK, La Roche-Posay, Leo Pharma, Louis Widmer, Meda Pharma BV, Molnlycke, Neutral huidverzorging, Novartis Pharma BV, Roche, Schering-Plough, Vichy, Wyeth Pharmaceuticals.